865 related articles for article (PubMed ID: 29491156)
41. APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription.
Chen Y; Hu J; Cai X; Huang Y; Zhou X; Tu Z; Hu J; Tavis JE; Tang N; Huang A; Hu Y
Antiviral Res; 2018 Jan; 149():16-25. PubMed ID: 29129707
[TBL] [Abstract][Full Text] [Related]
42. Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation.
Yang L; Wang YJ; Chen HJ; Shi LP; Tong XK; Zhang YM; Wang GF; Wang WL; Feng CL; He PL; Xu YB; Lu MJ; Tang W; Nan FJ; Zuo JP
Antiviral Res; 2016 Jan; 125():25-33. PubMed ID: 26611395
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
44. Compound IMB-Z inhibits hepatitis B virus replication through increasing APOBEC3G expression and incorporation into viral nucleocapsids.
Hu J; Wang H; Yang L; Wu S; Li Y; Li Y; Li Z
J Glob Antimicrob Resist; 2022 Dec; 31():371-378. PubMed ID: 36396043
[TBL] [Abstract][Full Text] [Related]
45. G to A hypermutation of hepatitis B virus.
Noguchi C; Ishino H; Tsuge M; Fujimoto Y; Imamura M; Takahashi S; Chayama K
Hepatology; 2005 Mar; 41(3):626-33. PubMed ID: 15726649
[TBL] [Abstract][Full Text] [Related]
46. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
47. A3G-induced mutations show a low prevalence and exhibit plus-strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
Ren F; Li W; Zhao S; Wang L; Wang Q; Li M; Xiang A; Guo Y
J Med Virol; 2021 Jun; 93(6):3672-3678. PubMed ID: 32779759
[TBL] [Abstract][Full Text] [Related]
48. TGF-β triggers HBV cccDNA degradation through AID-dependent deamination.
Qiao Y; Han X; Guan G; Wu N; Sun J; Pak V; Liang G
FEBS Lett; 2016 Feb; 590(3):419-27. PubMed ID: 26867650
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy.
Caballero A; Tabernero D; Buti M; Rodriguez-Frias F
Antiviral Res; 2018 Oct; 158():34-44. PubMed ID: 30059722
[TBL] [Abstract][Full Text] [Related]
50. Deaminase-Dead Mouse APOBEC3 Is an
Stavrou S; Zhao W; Blouch K; Ross SR
J Virol; 2018 Jun; 92(11):. PubMed ID: 29593034
[TBL] [Abstract][Full Text] [Related]
51. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.
Tang L; Sheraz M; McGrane M; Chang J; Guo JT
PLoS Pathog; 2019 Apr; 15(4):e1007742. PubMed ID: 31026293
[TBL] [Abstract][Full Text] [Related]
52. Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis.
McDaniel YZ; Patterson SE; Mansky LM
Antiviral Res; 2019 Oct; 170():104540. PubMed ID: 31247245
[TBL] [Abstract][Full Text] [Related]
53. Biogenesis and molecular characteristics of serum hepatitis B virus RNA.
Shen S; Xie Z; Cai D; Yu X; Zhang H; Kim ES; Zhou B; Hou J; Zhang X; Huang Q; Sun J; Guo H
PLoS Pathog; 2020 Oct; 16(10):e1008945. PubMed ID: 33079954
[TBL] [Abstract][Full Text] [Related]
54. Evidence for multiple distinct interactions between hepatitis B virus P protein and its cognate RNA encapsidation signal during initiation of reverse transcription.
Feng H; Chen P; Zhao F; Nassal M; Hu K
PLoS One; 2013; 8(8):e72798. PubMed ID: 23977352
[TBL] [Abstract][Full Text] [Related]
55. Region-Specific Hepatitis B Virus Genome Exposure from Nucleocapsid Modulated by Capsid Linker Sequence and Inhibitor: Implications for Uncoating.
Xi J; Cui X; Liu K; Liu H; Wang J; Hu J
J Virol; 2022 Apr; 96(8):e0039922. PubMed ID: 35389266
[TBL] [Abstract][Full Text] [Related]
56. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.
Mani N; Cole AG; Phelps JR; Ardzinski A; Cobarrubias KD; Cuconati A; Dorsey BD; Evangelista E; Fan K; Guo F; Guo H; Guo JT; Harasym TO; Kadhim S; Kultgen SG; Lee ACH; Li AHL; Long Q; Majeski SA; Mao R; McClintock KD; Reid SP; Rijnbrand R; Snead NM; Micolochick Steuer HM; Stever K; Tang S; Wang X; Zhao Q; Sofia MJ
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555628
[TBL] [Abstract][Full Text] [Related]
57. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
58. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
[TBL] [Abstract][Full Text] [Related]
59. [Comparative analysis of drug resistant mutations in the reverse transcriptase domain of hepatitis B virus covalently closed circular DNA and the viral relax circle DNA].
Su HL; Liu YM; Ren XQ; Xu DP; Zhong YW
Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):818-21. PubMed ID: 21138628
[TBL] [Abstract][Full Text] [Related]
60. Distribution and difference of APOBEC-induced mutations in the TpCpW context of HBV DNA between HCC and non-HCC.
Ren F; Li W; Xiang A; Wang L; Li M; Guo Y
J Med Virol; 2020 Jan; 92(1):53-61. PubMed ID: 31429946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
